Stephen Bloch Sells 75,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 75,000 shares of the stock in a transaction dated Tuesday, July 21st. The shares were sold at an average price of $79.99, for a total value of $5,999,250.00. Following the completion of the sale, the director owned 701,477 shares of the company’s stock, valued at approximately $56,111,145.23. This trade represents a 9.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Liquidia Price Performance

LQDA stock opened at $86.82 on Thursday. Liquidia Corporation has a 52 week low of $16.82 and a 52 week high of $91.10. The firm has a 50 day moving average of $72.81 and a 200 day moving average of $51.36. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The stock has a market capitalization of $7.72 billion, a PE ratio of 620.19 and a beta of 0.55.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, May 11th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.41 by $0.11. The firm had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Sell-side analysts forecast that Liquidia Corporation will post 3.02 earnings per share for the current year.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will report its second-quarter 2026 financial results on August 12, 2026. The update should provide investors with insight into YUTREPIA sales, operating performance and the company’s outlook. Liquidia Second Quarter 2026 Results Announcement
• Positive Sentiment: LifeSci Capital maintained a Buy rating, while Buckley Capital Advisors cited potential upside of more than 50% based on a prospective YUTREPIA ruling and possible buyout interest. These views support the bullish case, although they depend on regulatory and strategic outcomes. LifeSci Capital Buy Rating Buckley Capital Liquidia Investor Letter
• Neutral Sentiment: Recent coverage highlights a valuation debate: YUTREPIA could drive substantial growth, but patent risks and the stock’s elevated valuation may limit further gains. Shares trade at roughly 620 times earnings, making execution especially important.
• Negative Sentiment: Several insiders reported sales. Director Stephen Bloch sold 178,596 shares for about $15.2 million across July 20–23, while Jason Adair and Chief Accounting Officer Dana Boyle sold smaller amounts on July 27. The latter transactions were conducted under Rule 10b5-1 plans to cover tax withholding, reducing their negative significance; nevertheless, the director’s larger sales may encourage profit-taking concerns. Liquidia Insider Sales SEC Filing

Institutional Investors Weigh In On Liquidia

Several hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. Covestor Ltd increased its position in shares of Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after purchasing an additional 359 shares during the last quarter. PNC Financial Services Group Inc. increased its stake in Liquidia by 7.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 6,304 shares of the company’s stock worth $217,000 after purchasing an additional 422 shares during the period. Quantinno Capital Management LP lifted its position in shares of Liquidia by 3.6% during the first quarter. Quantinno Capital Management LP now owns 17,165 shares of the company’s stock worth $648,000 after purchasing an additional 589 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia during the 4th quarter worth approximately $25,000. Finally, ProShare Advisors LLC boosted its holdings in Liquidia by 7.1% in the fourth quarter. ProShare Advisors LLC now owns 11,756 shares of the company’s stock valued at $405,000 after purchasing an additional 775 shares during the period. Institutional investors and hedge funds own 64.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LQDA. Wall Street Zen lowered Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Oppenheimer set a $75.00 price objective on Liquidia in a research report on Friday, June 5th. Stephens set a $130.00 price objective on shares of Liquidia in a report on Friday, July 24th. Piper Sandler set a $129.00 target price on Liquidia in a report on Friday, July 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $86.18.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).